Cell No. : Cell Name
RCB3541 : ATL-72/2(+)
update : 2024/10/02
|
Comment | BSL2. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2. |
Comment from the depositor | ATL patient derived non-leukemic cell line (IL-2 dependent). ATL-72/2(+), ATL-72/2(-), ATL-72b(+), ATL-72b(-), ATL-72T(+) cell lines were established from the same patient's blood. |
Terms and conditions | 1) The material will be used for teaching or not-for profit research purpose only. To use the material for commercial purpose, he/she should refer to the establisher of the material. 2) The material will not be further distributed to others without the provider’s written consent. |
Remarks | |
Order Form |
Order Form(C-0005.pdf)
 
MTA(C-0007.pdf)
 
MTA(C-0007p.pdf)
 
Cell line to be handled at BSL 2(C-0070.pdf)
 
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
Basic information
|
Depositor |
MAEDA, Michiyuki
|
Originator |
MAEDA, Michiyuki
|
Year of deposit |
2011
|
Animal |
_human
< Mammals
|
Genus |
Homo
|
Species |
sapiens
|
Race |
Japanese
|
Tissue |
peripheral blood
|
Disease name |
ATL
|
Classification |
cancer
|
Year of origin |
1998
|
|
Lifespan |
infinite
|
Morphology |
lymphocyte-like
|
Product |
HTLV-1 pro-virus DNA(+)
|
Surface antigen (depositor) |
T cell marker (+), CD25 (+), HLA-DR (+)
|
BSL |
BSL2
|
Cellosaurus(Expasy) |
CVCL_A6TA
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
Suspension cells
|
Suspension cells
|
Culture method |
|
浮遊細胞の培養に関する一般的な注意(Japanese)
|
Culture medium |
10%FCS, RPMI1640, 7.5-15mg/ml human rIL-2
|
RPMI1640 + 10% FBS + 15ng/ml human rIL-2
|
Antibiotics |
100μg/ml kanamycin
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage cell No |
1-2 x 10 5 cells/ml
|
|
Passage ratio |
1 : 5-10 split
|
1 : 10 split
|
SC frequency |
Subculture : 2 times/week
|
Subculture : 2 times/week
|
Temperature |
37
℃
|
37
℃
|
CO2 concentration |
5
%
|
5
%
|
Freeze medium |
CELLBANKER
|
CELLBANKER 1
|
Freezing method |
|
Slow freezing
|
Mycoplasma |
|
(-)
|
Animal PCR |
|
OK
|
Virus (HIV) |
|
Undetected
|
Virus (HTLV-1) |
|
DNA (+)
|
Virus (EBV) |
|
(-)
|
Saturation density |
5-10 x 10 5 cells/ml
|
|
STR(human) |
|
OK
|
|
deposit info
|
|
lot info
|
D5S818 |
D13S317 |
D7S820 |
D16S539 |
vWA |
TH01 |
Amelogenin |
TPOX |
CSF1PO |
9
|
8,11
|
12
|
10
|
14,16
|
6,9
|
X
|
11
|
10,12
|
|
Reference information |
Reference |
2
|
User's Publication |
0
|
Reference |
3175
Michiyuki Maeda, Junko Tanabe-Shibuya, Paola Miyazato, Hiroshi Masutani, Jun-Ichirou Yasunaga, Kazumasa Usami, Akira Shimizu, Masao Matsuoka
IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia
Front Microbiol
2020
11:356
PubMed ID: 32210945
DOI: 10.3389/fmicb.2020.00356
|
2508
Matsuoka S, Ishii Y, Nakao A, Abe M, Ohtsuji N, Momose S, Jin H, Arase H, Sugimoto K, Nakauchi Y, Masutani H, Maeda M, Yagita H, Komatsu N, Hino O.
Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation
PLoS One
2016
11(3):e0150496.
PubMed ID: 27028595
DOI: 10.1371/journal.pone.0150496
|